We are live on ! Find out more
MVM

Medicxi Ventures Management Portfolio holdings

AUM $982M
1-Year Est. Return 210.17%
This Fund
S&P 500
This Quarter Est. Return
+0.51%
1 Year Est. Return
+210.17%
3 Year Est. Return
+787.54%
5 Year Est. Return
+404.19%
10 Year Est. Return
–
AUM
$558M
AUM Growth
+$386M
Cap. Flow
+$421M
Cap. Flow %
75.49%
Top 10 Hldgs %
100%
Holding
6
New
1
Increased
–
Reduced
–
Closed
–

Top Buys

Rank Stock Value
1
CNTA
Centessa Pharmaceuticals
CNTA
+$421M

Top Sells

No sells this quarter

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CNTA
1
DELISTED
Centessa Pharmaceuticals
CNTA
$398M 71.34%
+17,923,892
New +$421M
PHAT icon
2
Phathom Pharmaceuticals
PHAT
$708M
$70M 12.54%
2,067,861
– –
PCVX icon
3
Vaxcyte
PCVX
$7.81B
$42.5M 7.61%
1,887,478
– –
MRUS
4
DELISTED
Merus
MRUS
$33.7M 6.04%
1,600,000
– –
CMPI
5
DELISTED
Checkmate Pharmaceuticals, Inc. Common Stock
CMPI
$8.95M 1.6%
1,501,716
– –
OBSV
6
DELISTED
ObsEva SA Ordinary Shares
OBSV
$4.76M 0.85%
1,570,000
– –

Similar funds

BIP
Blueprint Investment Partners Greensboro, North Carolina $980M AUM 27.19% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return
PCM
Politan Capital Management New York $985M AUM 3.12% 1-Year Est. Return
MFWP
Mosaic Family Wealth Partners St. Louis, Missouri $977M AUM 19.09% 1-Year Est. Return
FCM
Fortis Capital Management Bellevue, Washington $977M AUM 17.17% 1-Year Est. Return
FFS
Forge Financial Services Edmond, Oklahoma $987M AUM 14.12% 1-Year Est. Return
PCM
Polymer Capital Management New York $988M AUM 56.33% 1-Year Est. Return
RCG
Rock Creek Group Washington, District of Columbia $988M AUM 8.89% 1-Year Est. Return

Medicxi Ventures Management's Q2 2021 Portfolio in Review

As of Q2 2021, Medicxi Ventures Management held 6 positions worth $558M, up 225% from $172M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Medicxi Ventures Management deployed $421M of net new capital in Q2 2021, opening 1 new position. Its largest new stake was Centessa Pharmaceuticals: 17,923,892 shares worth $398M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • Medicxi Ventures Management's largest Q2 2021 buy was Centessa Pharmaceuticals: 17,923,892 shares worth $398M.
  • Medicxi Ventures Management's ten largest holdings make up 100% of its $558M portfolio in Q2 2021.
  • Medicxi Ventures Management opened 1 new position and closed 0 in Q2 2021.
  • Medicxi Ventures Management's portfolio value rose 225% quarter-over-quarter to $558M.

Based on Medicxi Ventures Management's 13F filing for Q2 2021, filed 3 Aug 2021.